Tyrosinemia Type I
A rare inherited disorder of tyrosine metabolism caused by FAH gene variants, which can lead to liver and kidney dysfunction without early diagnosis and treatment with nitisinone and dietary management.
- Newborn screening detectable
- Treatable with nitisinone
- Specialist liver and kidney monitoring
- Inheritance Pattern
- Autosomal Recessive
- Affected Gene
- FAH
- Key Therapy
- Nitisinone (NTBC)
- Advanced Therapies
- Liver Transplant, Gene Therapy Research
Condition Overview
Tyrosinemia type I is a rare inherited disorder caused by variants in the FAH gene, which encodes fumarylacetoacetate hydrolase, the final enzyme in the tyrosine breakdown pathway. Deficiency of this enzyme leads to accumulation of toxic intermediates, particularly succinylacetone, which damages the liver, kidneys, and peripheral nerves.
Without treatment, tyrosinemia type I can cause severe liver disease in infancy, kidney tubular dysfunction, and an increased risk of liver cancer (hepatocellular carcinoma) over time. The introduction of nitisinone (NTBC), which blocks an earlier step in the pathway and prevents toxic metabolite formation, has dramatically improved outcomes when combined with a low-tyrosine, low-phenylalanine diet.
Tyrosinemia type I is included in many newborn screening programs through detection of elevated succinylacetone, allowing treatment to begin before significant organ damage occurs in many cases. Lifelong monitoring of liver and kidney function remains an important part of ongoing care.
Types and Presentations
Tyrosinemia type I presentation is generally grouped by age of onset and severity of liver involvement.
Symptoms and Signs
Symptoms relate primarily to liver, kidney, and sometimes nerve involvement, and can range from severe in infancy to more insidious in later presentations.
Causes and Risk Factors
Tyrosinemia type I is caused by inherited enzyme deficiency in the tyrosine degradation pathway, with disease severity influenced by timing of treatment.
Diagnosis and Investigations
Diagnosis combines biochemical testing for succinylacetone, genetic confirmation, and assessment of liver and kidney involvement.
Risk Stratification
Tyrosinemia type I is risk-stratified by liver disease severity at diagnosis and ongoing hepatocellular carcinoma risk rather than a traditional staging system.
Standard Treatment Approach
Treatment centers on nitisinone therapy combined with a low-tyrosine, low-phenylalanine diet, alongside regular surveillance for liver and kidney complications.
Advanced and Emerging Treatment Options
For patients diagnosed late or with significant liver disease, additional therapies beyond nitisinone and diet may be considered.
Surgical / Transplant
Liver transplantation
Considered in patients with advanced liver disease, suspicious or confirmed hepatocellular carcinoma, or those diagnosed too late for nitisinone to prevent significant damage.
Precision Medicine
Genotype-informed monitoring intensity
FAH variant type and age at treatment initiation can help inform individualized surveillance intensity.
Gene Therapy
Investigational gene-based therapies
Early-phase research is exploring gene replacement and gene-editing approaches aiming at restoring FAH enzyme function.
Oncologic Surveillance
Hepatocellular carcinoma screening program
Structured liver imaging and biomarker surveillance to detect early liver cancer in at-risk patients.
Biomarkers and Precision Monitoring
Specific metabolic and tumor surveillance markers guide diagnosis and long-term monitoring of tyrosinemia type I.
When a Second Opinion May Be Important
Given the complexity of tyrosinemia type I and its cancer risk implications, specialist second opinions can be valuable at key decision points.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Since the introduction of nitisinone, outcomes for tyrosinemia type I have improved substantially, particularly when treatment begins early, though long-term liver cancer surveillance remains important.
Supportive Care and Living With Tyrosinemia Type I
Day-to-day management requires coordinated dietary, medical, and surveillance support.
How CancerFax Helps You Explore Treatment Options
CancerFax helps connect patients and families with metabolic and hepatology specialists experienced in tyrosinemia type I and supports coordination of liver cancer surveillance and transplant evaluation where needed.
Get a free case reviewFrequently Asked Questions
Tyrosinemia type I is a rare inherited disorder caused by FAH gene variants that impair tyrosine breakdown, leading to toxic metabolite buildup that can damage the liver and kidneys.
Signs can include poor weight gain, jaundice, abdominal swelling, and bone changes related to kidney tubular dysfunction, though many cases are identified through newborn screening before symptoms occur.
Treatment combines nitisinone (NTBC), which blocks toxic metabolite formation, with a low-tyrosine, low-phenylalanine diet.
Yes, untreated or late-treated tyrosinemia type I increases the risk of hepatocellular carcinoma, which is why regular liver surveillance is an important part of long-term care.
Yes, it is included in many newborn screening programs through detection of elevated succinylacetone.
Liver transplantation may be considered in patients with advanced liver disease or suspicious liver nodules, and is discussed individually with a transplant-experienced metabolic team.
Yes, it is inherited in an autosomal recessive pattern, caused by variants in the FAH gene.
Yes, nitisinone is typically continued lifelong alongside dietary management to prevent toxic metabolite accumulation.
Gene-based therapies remain investigational and are being studied in clinical trials rather than offered as standard treatment.
Yes. CancerFax can help review your medical reports, coordinate a second opinion with metabolic and hepatology specialists, and help identify centers experienced in managing tyrosinemia type I, including liver transplant evaluation and cross-border coordination where needed.
Managing Tyrosinemia Type I?
Get coordinated specialist support for nitisinone therapy and liver surveillance.